IL188688A0 - Plexin d1 as a target for tumor diagnosis and therapy - Google Patents

Plexin d1 as a target for tumor diagnosis and therapy

Info

Publication number
IL188688A0
IL188688A0 IL188688A IL18868808A IL188688A0 IL 188688 A0 IL188688 A0 IL 188688A0 IL 188688 A IL188688 A IL 188688A IL 18868808 A IL18868808 A IL 18868808A IL 188688 A0 IL188688 A0 IL 188688A0
Authority
IL
Israel
Prior art keywords
plexin
therapy
target
tumor diagnosis
tumor
Prior art date
Application number
IL188688A
Original Assignee
Stichting Katholieke Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Katholieke Univ filed Critical Stichting Katholieke Univ
Publication of IL188688A0 publication Critical patent/IL188688A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
IL188688A 2005-07-21 2008-01-09 Plexin d1 as a target for tumor diagnosis and therapy IL188688A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05076675 2005-07-21
PCT/EP2006/007241 WO2007009816A2 (en) 2005-07-21 2006-07-20 Plexin d1 as a target for tumor diagnosis and therapy

Publications (1)

Publication Number Publication Date
IL188688A0 true IL188688A0 (en) 2008-08-07

Family

ID=37115996

Family Applications (1)

Application Number Title Priority Date Filing Date
IL188688A IL188688A0 (en) 2005-07-21 2008-01-09 Plexin d1 as a target for tumor diagnosis and therapy

Country Status (12)

Country Link
US (4) US20100119445A1 (en)
EP (1) EP1907420B1 (en)
JP (1) JP2009506985A (en)
CN (1) CN101287758A (en)
AU (1) AU2006271880A1 (en)
BR (1) BRPI0613425A2 (en)
CA (1) CA2615744C (en)
DK (1) DK1907420T3 (en)
ES (1) ES2632360T3 (en)
IL (1) IL188688A0 (en)
PL (1) PL1907420T3 (en)
WO (1) WO2007009816A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091378A1 (en) * 2008-01-10 2009-10-14 Genentech Inc PLEXIND1 AGONIST POLYPEPTIDES
US8512944B2 (en) * 2008-08-27 2013-08-20 Oncotherapy Science, Inc. PRMT1 for target genes of cancer therapy and diagnosis
CN101914542B (en) * 2009-04-28 2013-03-06 中国科学院化学研究所 Aptamer for typing different non-small cell lung cancer subtypes and screening method thereof
EP2385121A1 (en) * 2010-05-06 2011-11-09 Netris Pharma Antagonists of Sema3E/PlexinD1 interaction as anti-cancer agents
EP2487242A1 (en) 2011-02-09 2012-08-15 Ruprecht-Karls-Universität Heidelberg B-type plexin antagonists and uses thereof
CA2912801A1 (en) * 2013-05-17 2014-11-20 Medimmune, Llc Receptors for b7-h4
WO2016092082A1 (en) 2014-12-11 2016-06-16 Modiquest B.V. Method for the treatment of idiopathic pulmonary fibrosis
CN106967789A (en) * 2017-01-26 2017-07-21 上海长海医院 A kind of prostate cancer marker PLXNA1 and its application
WO2018190365A1 (en) * 2017-04-12 2018-10-18 国立大学法人九州大学 Neuropathic pain marker and use thereof
EP3693380A1 (en) 2019-02-11 2020-08-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Dual inhibition of plexin-b1 and plexin-b2
CN117659171A (en) * 2022-09-07 2024-03-08 东莞市朋志生物科技有限公司 anti-HBeAg antibody or functional fragment thereof, reagent for detecting HBeAg and kit
CN116459356B (en) * 2023-04-24 2024-03-19 中国人民解放军总医院第一医学中心 Multi-mode molecular imaging nano probe for early warning and dynamic monitoring of atherosclerosis plaque and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
AU7073800A (en) * 1999-08-25 2001-03-19 Regents Of The University Of California, The Novel plexins and uses thereof
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
AU2001268855A1 (en) * 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
AU2003262717A1 (en) * 2002-08-15 2004-03-03 Genzyme Corporation Brain endothelial cell expression patterns
SE0203137D0 (en) * 2002-10-24 2002-10-24 Karolinska Innovations Ab Drug target in cancer therapy
WO2004053157A2 (en) * 2002-12-12 2004-06-24 Novartis Ag Methods for diagnosing and treating schizophrenia
US20070054271A1 (en) * 2003-03-20 2007-03-08 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
US7482322B2 (en) * 2003-10-30 2009-01-27 Kazusa Dna Research Institute Foundation Plexin family-like polypeptide, and uses thereof
DE102004037860A1 (en) * 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker for the diagnosis of carcinomas and / or derived metastases

Also Published As

Publication number Publication date
PL1907420T3 (en) 2017-09-29
DK1907420T3 (en) 2017-07-17
AU2006271880A1 (en) 2007-01-25
ES2632360T3 (en) 2017-09-12
JP2009506985A (en) 2009-02-19
BRPI0613425A2 (en) 2012-10-30
US9988449B2 (en) 2018-06-05
EP1907420A2 (en) 2008-04-09
CA2615744C (en) 2018-03-27
WO2007009816A3 (en) 2007-03-29
EP1907420B1 (en) 2017-04-05
US20100119445A1 (en) 2010-05-13
CN101287758A (en) 2008-10-15
CA2615744A1 (en) 2007-01-25
WO2007009816A2 (en) 2007-01-25
US9422358B2 (en) 2016-08-23
US20160311900A1 (en) 2016-10-27
US20180319882A1 (en) 2018-11-08
US20120321554A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
IL188688A0 (en) Plexin d1 as a target for tumor diagnosis and therapy
HK1205935A1 (en) Non-lithotripsic kidney-stone therapy
GB0519405D0 (en) Cancer therapy prognosis and target
IL186662A0 (en) Combination cancer therapy with
EP1718145A4 (en) Conjugates for cancer therapy and diagnosis
ZA200804918B (en) Therapeutic vaccine
EP2004230A4 (en) N-cadherin and ly6 e: targets for cancer diagnosis and therapy
EP1996699A4 (en) Cancerous disease modifying antibodies
IL212800A0 (en) N-cadherin: target for cancer diagnosis and therapy
EP1871166A4 (en) Cancer vaccines and therapeutic methods
GB2443588B (en) A pharmaceutical composition useful for the treatment of prostate cancer
EP2044119A4 (en) Cancerous disease modifying antibodies
EP1966607A4 (en) Mac-2bp as a marker for the diagnosis of gastric cancer
GB0700645D0 (en) Targets for disease therapy
EP2136820A4 (en) A target for breast cancer therapy and/or diagnosis
EP2352825A4 (en) C12orf48 as a target gene for cancer therapy and diagnosis
EP2231184A4 (en) Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neaural and glial tumors of the brain
IL198312A0 (en) Cancerous disease modifying antibodies
ZA200706871B (en) Treatment of metastasized tumors
ZA200903281B (en) Cancerous disease modifying antibodies
AU2007901124A0 (en) A target for breast cancer therapy and/or diagnosis
GB0501202D0 (en) Targets for therapy
GB0421918D0 (en) Cancer therapeutic target
GB0400803D0 (en) A target for the treatment of disease
GB0700649D0 (en) Targets for disease therapy